The Spartanburg Community Clinical Oncology Program (SCCOP) comprised of the above named clinical investigators and support personnel, working through a consortium arrangement with three component hospitals and with physicians and support personnel from a variety of disciplines in the community, will: 1) provide support for expanding the clinical research effort in the community setting; 2) stimulate quality care in the community through participation in protocol studies; and 3) foster the growth and development of a scientifically viable community cancer network able to work closely with NCI-supported cooperative groups and university cancer centers. In addition, SCCOP will: 1) provide support for cancer control research in the community, 2) provide an operational base for the extension of cancer control efforts in early detection, prevention, screening, pretreatment evaluation, treatment, continuing care and rehabilitation; 3) involve primary care providers and other specialists in cancer control studies early in the coarse of clinical treatment; 4) increase involvement of minority and underserved populations in clinical research; and 5) evaluate the SCCOP performance and its impact on the community. It is proposed to achieve these goals by meeting the following objectives: 1) to affiliate with the Southwest Oncology Group (primary research base), Oncology Research Center/Bowman Gray School of Medicine (cancer center), and the National Surgical Adjuvant Breast and Bowel Project; 2) to accrue a minimum of 50 credits per year to NCI-approved treatment protocols provided through these research groups; 3) to participate in cancer control studies activated by the research bases and accrue at least 20 credits the first year, 30 credits the second year, and 50 credits the third year. Support for CCOP activities will be provided by 4- full-time staff. A successful SCCOP will: 1) bring advantageous treatment and cancer control research to individuals in their own communities by having practicing physician oncologists utilize appropriate NCI-approved protocols; 2) involve a wider segment of our community in such research and evaluate the impact in community medical practices; and 3) by increasing the involvement of primary health providers and specialists with SCCOP investigators and facilitating wider community participation, reduce cancer mortality by accelerating the transfer of newly developed cancer prevention, detection, treatment, and continuing care technology to our community.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA035119-06
Application #
3557528
Study Section
(SRC)
Project Start
1983-09-01
Project End
1990-05-31
Budget Start
1989-06-01
Budget End
1990-05-31
Support Year
6
Fiscal Year
1989
Total Cost
Indirect Cost
Name
Spartanburg Regional Medical Center
Department
Type
DUNS #
052072048
City
Spartanburg
State
SC
Country
United States
Zip Code
29303
Barton, Debra L; Sloan, Jeff A; Shuster, Lynne T et al. (2018) Evaluating the efficacy of vaginal dehydroepiandosterone for vaginal symptoms in postmenopausal cancer survivors: NCCTG N10C1 (Alliance). Support Care Cancer 26:643-650
West, Howard L; Moon, James; Wozniak, Antoinette J et al. (2018) Paired Phase II Studies of Erlotinib/Bevacizumab for Advanced Bronchioloalveolar Carcinoma or Never Smokers With Advanced Non-Small-cell Lung Cancer: SWOG S0635 and S0636 Trials. Clin Lung Cancer 19:84-92
Hussain, Maha; Tangen, Catherine M; Thompson Jr, Ian M et al. (2018) Phase III Intergroup Trial of Adjuvant Androgen Deprivation With or Without Mitoxantrone Plus Prednisone in Patients With High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921. J Clin Oncol 36:1498-1504
Persky, Daniel O; Li, Hongli; Rimsza, Lisa M et al. (2018) A phase I/II trial of vorinostat (SAHA) in combination with rituximab-CHOP in patients with newly diagnosed advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0806. Am J Hematol 93:486-493
Danilov, Alexey V; Li, Hongli; Press, Oliver W et al. (2017) Feasibility of interim positron emission tomography (PET)-adapted therapy in HIV-positive patients with advanced Hodgkin lymphoma (HL): a sub-analysis of SWOG S0816 Phase 2 trial. Leuk Lymphoma 58:461-465
Liu, Xiaonan; Li, Jing; Schild, Steven E et al. (2017) Statins and Metformin Use Is Associated with Lower PSA Levels in Prostate Cancer Patients Presenting for Radiation Therapy. J Cancer Ther 8:73-85
Moinpour, Carol M; Unger, Joseph M; Ganz, Patricia A et al. (2017) Seven-year follow-up for energy/vitality outcomes in early stage Hodgkin's disease patients treated with subtotal lymphoid irradiation versus chemotherapy plus radiation: SWOG S9133 and its QOL companion study, S9208. J Cancer Surviv 11:32-40
Heinrich, Michael C; Rankin, Cathryn; Blanke, Charles D et al. (2017) Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033. JAMA Oncol 3:944-952
Sio, Terence T; Atherton, Pamela J; Birckhead, Brandon J et al. (2016) Repeated measures analyses of dermatitis symptom evolution in breast cancer patients receiving radiotherapy in a phase 3 randomized trial of mometasone furoate vs placebo (N06C4 [alliance]). Support Care Cancer 24:3847-55
Nahleh, Z A; Barlow, W E; Hayes, D F et al. (2016) SWOG S0800 (NCI CDR0000636131): addition of bevacizumab to neoadjuvant nab-paclitaxel with dose-dense doxorubicin and cyclophosphamide improves pathologic complete response (pCR) rates in inflammatory or locally advanced breast cancer. Breast Cancer Res Treat 158:485-95

Showing the most recent 10 out of 202 publications